Accessing Library
Connecting to Pep Nation Lab's research database...
Connecting to Pep Nation Lab's research database...
Select Up To Four Compounds To Review Their Evidence, Targets, And Handling Side By Side.
For Laboratory Research Only
| Attribute | ||
|---|---|---|
Research Summary | Think of BPC-157 as the ultimate "Fix-It" mechanic for your body. Whether it is a torn muscle, a sore joint, or a damaged stomach, it rushes to the site and speeds up the healing process incredibly fast. | KPV is the ultimate inflammation cooler. When your immune system is freaking out and causing red, swollen, angry issues (like in the gut or on the skin), KPV acts like a fire extinguisher to instantly calm it down. |
Studied For | GI mucosal healingTendon / ligament repairNerve repairAnti-inflammatoryGut health and integrityLeaky gut researchIBD / Crohn's disease modelsUlcerative colitis modelsGastric ulcer healingIntestinal anastomosis healingWound healing accelerationMuscle tear recoverySports injury recoveryJoint inflammation reductionBone healingCartilage repairNeurological recoverySpinal cord injury modelsPeripheral nerve regenerationAngiogenesis promotionBlood pressure regulationNitric oxide pathwayGrowth hormone receptor upregulationCytoprotectionSystemic healingNSAID-induced gastric damage reversalAlcohol-induced gut damage reversalPost-surgical healingScar reductionAnti-ulcer researchjoint healinggut healingtendon repairulcer repairligament healingmuscle tear recoveryleaky gutinflammation reductionpain reliefsoft tissue repair | GI inflammation / IBD researchUlcerative colitis modelsCrohn's disease modelsSkin inflammationWound healingImmune modulationNF-kB pathway inhibitionAnti-inflammatory cytokine reductionMucosal barrier integrityGut health restorationPsoriasis researchEczema researchColitis modelsMelanocortin receptor anti-inflammatorySystemic inflammation reductionOral peptide delivery researchanti-inflammatorygut healingCandidaIBDpsoriasismast cell stabilizationskin healingulcerative colitis |
Research Areas | Healing & RecoveryTissue RepairGut Health & GI RepairPain & InflammationJoint & Bone SupportImmune | Gut Health & GI RepairImmuneHealing & RecoveryPain & InflammationSkin & Hair |
Best Stacked With | tb-500ghk-cukpvll-37bac-water | bpc-157ll-37thymosin-alpha-1lipo-cbac-water |
Overview | ||
Category | Healing & Recovery | Healing & Recovery |
Compound Class | Synthetic pentadecapeptide derived from human gastric juice protein BPC | Tripeptide C-terminal fragment of alpha-MSH (melanocyte-stimulating hormone) |
Molecular Target | NO-synthase, VEGF, FAK/paxillin, EGF receptor, growth hormone receptor; promotes angiogenesis, collagen synthesis, and cytoprotection | MC1R / melanocortin receptors; NF-kB inhibition; reduces TNF-alpha, IL-1beta, IL-6 production; mucosal protection |
Aliases / AKA | Body Protection Compound 157BPC157BPC 157BPC-157Pentadecapeptide BPC 157Stable Gastric Pentadecapeptide | Lys-Pro-ValAlpha-MSH tripeptide coreMSH fragmentKPV peptideAlpha-melanocyte-stimulating hormone C-terminal tripeptideAnti-inflammatory tripeptide |
Parent Compound | Gastric juice BPC protein fragment | alpha-MSH C-terminal fragment |
Molecular Weight | 1419.5 Da | 342.43 Da |
Amino Acid Sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val | Lys-Pro-Val |
CAS Number | 137525-51-0 | 67727-97-3 |
Year Discovered | Not Listed | Not Listed |
Pro-Angiogenic | Yes - Promotes New Vessel Growth | No |
GLP-1 Class | No | No |
Purity | Not Listed | Not Listed |
Identity | ||
Evidence Tier | ||
Risk Level | ||
PubMed Citations | 224 Good | 206 Good |
Clinical Trials | 22 Active | Not Listed |
Regulatory Status | Not FDA-approved; under FDA compounding-safety review (503A bulk-substances evaluation); research chemical. | Not FDA-approved; research chemical. |
Evidence & Regulatory | ||
Half-Life | ~30 minutes | ~1.5 hours |
Typical Frequency | Not Listed | Not Listed |
Administration Route | Injection Only | Injection Only |
Mechanism / PK | Not Listed | Not Listed |
Reported Findings | Evidence is overwhelmingly rodent and in vitro: accelerated healing, angiogenesis, and protection against NSAID gastrointestinal damage. Human evidence is very limited; injectable musculoskeletal claims are not established in humans. | Cell and mouse colitis studies report reduced inflammation and mucosal healing, often using targeted nanoparticle delivery. Human efficacy is not established. |
Side Effects Noted | Rodent toxicology is benign but human adverse-event data are essentially absent. FDA flags immunogenicity, unknown long-term effects, and a theoretical pro-angiogenic tumor-vascularization risk. | Preclinical tolerability is good with low toxicity; no meaningful human adverse-event data. |
Warnings | Not approved; flagged by the FDA under its 503A bulk-substances compounding-safety review. The pro-angiogenic mechanism is a theoretical concern in any malignancy. Research use only. | No approved human indication. Research use only. |
Pharmacology | ||
Form | lyophilized | lyophilized |
Diluent | bacteriostatic or sterile water; swirl, do not shake | sterile or bacteriostatic water |
Storage Temp | 2-8C; -20C long-term, dark | cold, dry |
Light Sensitive | Yes | Yes |
Freeze / Thaw | avoid | avoid |
Handling Notes | Reported stable in gastric juice; arginate salt aids stability. | Small, relatively stable tripeptide. |
Reconstituted Shelf Life | 28 Days Refrigerated | 28 Days Refrigerated |
Handling & Storage | ||
Pep Nation Lab's comparison tool puts research-grade peptides and compounds head to head - mechanism of action, molecular target, evidence tier, molecular weight, sequence, half-life, and documented research focus - so qualified researchers can evaluate the differences that matter. Every data point is drawn from a referenced monograph. For in vitro laboratory research use only.
The two most-studied research peptides for tissue repair and recovery.
Single GLP-1 versus dual GLP-1/GIP incretin agonists in metabolic research.
Dual versus triple incretin receptor agonists in weight-research models.
A GLP-1 agonist versus a triple-agonist incretin in metabolic research.
A GHRH analog versus a selective ghrelin-receptor secretagogue.
A ghrelin-receptor secretagogue versus a GHRH analog for growth-hormone research.
Two GHRH analogs studied on the growth-hormone axis.
The two first-generation growth-hormone releasing peptides.
An amylin analog versus a GLP-1 agonist in metabolic research.
A mitochondrial-derived peptide versus an HGH fragment in metabolic research.
Melanocortin versus kisspeptin pathways in reproductive research.
A telomerase-pathway peptide versus NAD+ metabolism in longevity research.
A potent versus a highly selective ghrelin-receptor secretagogue.
Two GHRH analogs with contrasting half-life profiles.
A direct IGF-1 analog versus a growth-hormone secretagogue.
The DAC versus non-DAC forms of the CJC-1295 GHRH analog.
Two Russian-developed nootropic and anxiolytic research peptides.
Two mitochondrial-targeted peptides in cellular-energy research.
Two immune-modulating research peptides with distinct mechanisms.
Two HGH-fragment analogs studied for fat-metabolism research.
Next-generation multi-receptor incretin agonists in metabolic research.
Two leading tissue-repair peptides with distinct healing mechanisms.
A systemic repair peptide versus a copper peptide for tissue and skin research.
A GHRH analog versus a selective ghrelin-receptor secretagogue on the GH axis.
A dual incretin agonist versus an amylin analog in metabolic research.
A triple incretin agonist versus an amylin analog in weight research.
Two metabolic research compounds targeting mitochondrial and NNMT pathways.
NAD+ metabolism versus a mitochondrial-derived peptide in longevity research.
Two copper research peptides studied for skin and hair.
A long-acting versus a short-acting GHRH analog.
A selective versus a first-generation ghrelin-receptor secretagogue.
A GLP-1 agonist versus a GLP-1/amylin combination in metabolic research.
Two peptides studied for gut and mucosal repair.
Melanocortin versus oxytocin pathways in intimacy and libido research.
Two thymic immune-modulating research peptides.
An anxiolytic nootropic versus a sleep-associated research peptide.
Direct IGF-1 signaling versus myostatin inhibition in muscle research.
A mitochondrial-targeted peptide versus NAD+ in cellular-energy research.
Browse the full research catalog or the A To Z index to compare any compound.
Any research-grade compound in the library can be placed side by side - up to four at a time. The tool compares mechanism of action, molecular target, evidence tier, molecular weight, amino acid sequence, reported half-life, and what each compound has been studied for, all drawn from referenced monographs.
The evidence tier reflects how extensively a compound has been studied in the referenced literature, from early preclinical signals through to compounds with human clinical data. It is a research-quality signal only, never a safety or efficacy endorsement.
Each comparison page is generated from the same referenced compound database - a genuine side-by-side of mechanism, identity, pharmacokinetics, and evidence, plus data-derived key differences. They are curated, not auto-generated thin pages.
No. Every comparison is for in vitro laboratory research use only. Nothing here is medical advice, a treatment recommendation, or dosing guidance, and no product is for human or animal consumption.
